Study Summary
This is a phase I, open-label, single-arm study conducted in China to evaluate the safety, tolerability, PK, and determine the recommended phase II dose (RP2D) and/or maximum tolerated dose (MTD) (if applicable) of JWCAR029 in pediatric and young adult subjects with r/r B-ALL.
Want to learn more about this trial?
Request More InfoInterventions
CD19-targeted Chimeric Antigen Receptor (CAR) T CellsBIOLOGICAL
Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (25 mg/m2/day for 3 days) plus cyclophosphamide IV (250 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JWCAR029 cells infusion. Phase 1 will evaluate up to 4 JWCAR029 cells dose levels.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hematology Hospital, Chinese Academy of Medical Sciences | Tianjin | Tianjin Municipality | China |